The Global Electroceutical Devices Market, by Product (Cardiac Pacemakers, Implantable Cardioverter Defibrillators, Retinal Implants, Cochlear Implants, Spinal cord Stimulators, Deep brain Stimulators, and Others), by Modality (Implantable Electroceutical Devices and Non-Invasive Electroceutical Devices), by Application (Pain Management, Wound Healing, Atrial Fibrillation, Coronary Artery Disease, Diabetes, Arthritis, Hypertension, Gastrointestinal Diseases, and Others Applications), By End User (Hospitals, Academic Research Institutions, and Ambulatory Surgical Centers), was valued US$ 17.8 billion in 2018, and is projected to exhibit a CAGR of 8.0% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Electroceuticals are medical devices, which employ electrical currents to affect and modify body functions as an alternative to drug-based interventions. In contrast to pacemakers and other classical excitable-tissue stimulators, modern electroceutical devices employ sophisticated control strategies in order to modulate physiological regulation. For instance, modulation of cardiac contractility as a therapy for heart failure, modulation of gastric contractility as a therapy for diabetes, and modulation of vagus nerve traffic as a therapy for epilepsy and inflammatory diseases.
Market players are actively investing in research and development to develop more efficient and innovative electroceutical devices and also retaining organic and in-organic strategies, which thereby offer lucrative opportunities in this market.
For instance, in November 2017, LivaNova PLC and MicroPort Scientific Corporation entered into a binding Letter of Intent (LOI) to sale LivaNova’s Cardiac Rhythm Management (CRM) business franchise to MicroPort for US$ 190 million. Company’s CRM product portfolio includes pacemakers, high-voltage defibrillators, and cardiac resynchronization therapy devices. The acquisition helps MicroPort to add these diverse cardiac rhythm management portfolio to their existing product portfolio.
In August 2014, Medtronic plc completed acquisition of Sapiens Steering Brain Stimulation (Sapiens SBS): a developer of Deep Brain Stimulation (DBS) technologies; for deal value of US$ 200 million. Moreover, acquisition of Sapiens SBS strengthens Medtronic's capabilities in modulation of brain function.
Browse 32 Market Data Tables and 36 Figures spread through 192 Pages and in-depth TOC on "Electroceutical Devices Market, by Product (Cardiac Pacemakers, Implantable Cardioverter Defibrillators, Retinal Implants, Cochlear Implants, Spinal cord Stimulators, Deep brain Stimulators and Others), by Modality (Implantable Electroceutical Devices and Non-Invasive Electroceutical Devices), by Application (Pain Management, Wound Healing, Atrial Fibrillation, Coronary Artery Disease, Diabetes, Arthritis, Hypertension, Gastrointestinal Diseases, and Other Applications), By End User (Hospitals, Academic Research Institutions, and Ambulatory Surgical Centers) - Global Forecast to 2026"
To know the latest trends and insights related to electroceutical devices market, click the link below:
Furthermore, key players are engaged in launching innovative electroceutical devices portfolio in market along with gaining regulatory approval for the same.
For instance, in November 2017, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for their portfolio of Azure pacemakers with BlueSync technology, which is available in both single and dual chamber cardiac pacemakers. Company’s new Azure XT MRI and Azure S MRI pacemakers offer improved longevity, which is an estimated at 13.7 years (dual chamber).
Moreover, in November 2017, Cochlear Limited; received the U.S.FDA approval for first remote feature to nucleus cochlear implant system thorough a telemedicine platform, which allow follow-up programming sessions. This approval is first in the artificial cochlear implant industry, benefiting various cochlear implant patients who are unable to access consistent follow-ups.
Furthermore, manufacturers of implantable cardiac pacemakers are updating their product portfolio by implementing inorganic growth strategies to sustain their foothold in the market. In April 2016, Medtronic plc received U.S.FDA approval for the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is based on miniaturized pacing technology, which allows it to be delivered through a catheter and implanted directly into the heart.
Key takeaways of the Electroceutical Devices Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.